Targeting sonic hedgehog-associated medulloblastoma through inhibition of aurora and polo-like kinases

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6310-6322

  Markant, Shirley L ^a,b,f   Esparza, Lourdes Adriana ^a,b   Sun, Jesse ^f,g   Barton, Kelly L ^f,h   McCoig, Lisa M ^f   Grant, Gerald A ^h,i   Crawford, John R ^c,d,e   Levy, Michael L ^b,e   Northcott, Paul A ^j,k   Shih, David ^k   Remke, Marc ^k   Taylor, Michael D ^k   Wechsler Reya, Robert J ^a,b,f  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f Med Pharmacol Cancer Biol H   (United States)

^g Division of Pulmonary Allergy and Critical Care   (United States)

^h Division of Hematology/Oncology   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; AURORA A KINASE; AURORA B KINASE; AURORA KINASE; CD15 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DANUSERTIB; HISTONE H3; POLO LIKE KINASE; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TOZASERTIB; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AURKA GENE; AURKB GENE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENESIS; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PLK1 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

ANIMALS; AURORA KINASE A; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL PROLIFERATION; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 84886018302     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4258     Document Type: Article

References (54)

1. Merchant TE, Pollack IF, Loeffler JS Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 2010; 20:58-66.
2. Crawford JR, MacDonald TJ, Packer RJ Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007; 6:1073-85.
3. Pollack IF. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 2011; 8:135-48.
4. Taylor MD, Northcott PA, Korshunov A, Remke M., Cho YJ, Clifford SC, et al Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123:465-72.
5. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71:5057-61.
6. Rudin CM, Hann CL, Laterra J, Yauch R.L., Callahan CA, Fu L, et al Treatment of medulloblastoma with hedgehog pathway inhibitor GDC0449. N Engl J Med 2009; 361:1173-8.
7. Ramaswamy V, Northcott PA, Taylor MD FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 2011; 204:577-88.
8. Buonamici S, Williams J, Morrissey M., Wang A, Guo R, Vattay A., et al Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010; 2:51ra70.
9. Al-Hajj M., Wicha MS, Benito-Hernandez A, Morrison S.J., Clarke MF Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8.
10. Singh SK, Hawkins C, Clarke I.D., Squire JA, Bayani J, Hide T, et al Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
11. O'Brien C.A., Pollett A, Gallinger S., Dick JE A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-10.
12. Li C, Heidt DG, Dalerba P, Burant C.F., Zhang L., Adsay V, et al Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
13. Xin L, Lawson DA, Witte ON The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005; 102:6942-7.
14. + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106:16281-6.
15. + cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-66.
16. Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A 2011; 108:10544-9.
17. Alison MR, Lin WR, Lim S.M., Nicholson LJ Cancer stem cells: in the line of fire. Cancer Treat Rev 2012; 38:589-98.
18. Bao S, Wu Q, McLendon R.E., Hao Y., Shi Q, Hjelmeland AB, et al Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
19. +cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67.
20. Read TA, Fogarty MP, Markant S.L., McLendon RE, Wei Z, Ellison DW, et al Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009; 15:1-13.
21. Goodrich LV, Milenkovic L, Higgins K.M., Scott MP Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109-13.
22. Yang ZJ, Ellis T, Markant S.L., Read TA, Kessler JD, Bourboulas M, et al Medulloblastoma can be initiated by deletion of Patched in lineagerestricted progenitors or stem cells. Cancer Cell 2008; 14:135-45.
23. Tibshirani R, Hastie T, Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002; 99:6567-72.
24. Northcott PA, Shih DJ, Remke M, Cho Y.J., Kool M., Hawkins C, et al Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012; 123:615-26.
25. Chen Y, Stevens B, Chang J., Milbrandt J, Barres BA, Hell JW NS21: redefined and modified supplement B27 for neuronal cultures. J Neurosci Methods 2008; 171:239-47.
26. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008; 8:16.
27. Hsu JY, Sun ZW, Li X, Reuben M., Tatchell K, Bishop DK, et al Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000; 102:279-91.
28. Harrington EA, Bebbington D, Moore J., Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al VX-680, a potent and selective smallmolecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7.
29. Steegmaier M, Hoffmann M, Baum A., Lenart P, Petronczki M, Krssak M., et al BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-22.
30. Fink J, Sanders K, Rippl A., Finkernagel S, Beckers TL, Schmidt M. Cell type-dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Mol Cancer Ther 2007; 6:3189-97.
31. Miller-Moslin K., Peukert S, Jain R.K., McEwan MA, Karki R, Llamas L, et al 1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem 2009; 52: 3954-68.
32. Hofheinz RD, Al-Batran SE, Hochhaus A., Jager E, Reichardt VL, Fritsch H, et al An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010; 16:4666-74.
33. Sebastian M, Reck M, Waller C.F., Kortsik C., Frickhofen N, Schuler M, et al The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010; 5:1060-7.
34. Mross K, Frost A, Steinbild S., Hedbom S, Rentschler J, Kaiser R., et al Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26:5511-7.
35. Lens SM, Voest EE, Medema RH Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41.
36. Neben K, Korshunov A, Benner A., Wrobel G, Hahn M, Kokocinski F., et al Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64:3103-11.
37. Ali HR, Dawson SJ, Blows F.M., Provenzano E., Pharoah PD, Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ERpositive breast cancer. Br J Cancer 2012; 106:1798-806.
38. Lehman NL, O'Donnell JP, Whiteley LJ, Stapp R.T., Lehman TD, Roszka KM, et al Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 2012; 11:489-502.
39. Liang X, Wang D, Wang Y., Zhou Z, Zhang J, Li J. Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol 2012; 7:84.
40. Lin ZZ, Jeng YM, Hu F.C., Pan HW, Tsao HW, Lai PL, et al Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B overexpression in HCC. BMC Cancer 2010; 10:461.
41. King SI, Purdie CA, Bray S.E., Quinlan PR, Jordan LB, Thompson AM, et al Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res 2012; 14:R40.
42. Cheng MW, Wang BC, Weng Z.Q., Zhu XW Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochem 2012; 114:503-9.
43. Cheung CH, Coumar MS, Chang J.Y., Hsieh HP Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011; 21:857-84.
44. Chopra P, Sethi G, Dastidar S.G., Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010; 19:27-43.
45. Traynor AM, Hewitt M, Liu G., Flaherty KT, Clark J, Freedman SJ, et al Phase I dose escalation study of MK-0457, a novel aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67:305-14.
46. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T., Ahn CP, Holcomb T, et al Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-4.
47. Adolphe C, Hetherington R, Ellis T., Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res 2006; 66:2081-8.
48. Cayuso J, Ulloa F, Cox B., Briscoe J, Marti E. The Sonic hedgehog pathway independently controls the patterning, proliferation and survival of neuroepithelial cells by regulating Gli activity. Development 2006; 133:517-28.
49. Kenney AM, Rowitch DH Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol 2000; 20:9055-67.
50. Oliver TG, Grasfeder LL, Carroll A.L., Kaiser C., Gillingham CL, Lin SM, et al Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 2003; 100:7331-6.
51. Muscal JA, Scorsone KA, Zhang L, Ecsedy J.A., Berg SL Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs 2012; 31:39-45.
52. Harris PS, Venkataraman S, Alimova I., Birks DK, Donson AM, Knipstein J, et al Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 2012; 12:80.
53. El-Sheikh A., Fan R, Birks D., Donson A, Foreman NK, Vibhakar R. Inhibition of aurora kinase A enhances chemosensitivity of medulloblastoma cell lines. Pediatr Blood Cancer 2010; 55:35-41.
54. Northcott PA, Korshunov A, Witt H., Hielscher T, Eberhart CG, Mack S, et al Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-14.